Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 3 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready
Acies Bio D O O has 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 5 distinct examiners, which means each pending case is being reviewed by a different individual. This distribution suggests that the company's biotech filings are not being clustered under a single examiner.
The portfolio is active in 3 distinct art units. This concentration in 3 units, despite having 5 distinct examiners, indicates that some art units have multiple examiners assigned to the company's cases. Robinson, Hope A is the busiest examiner, holding 1 pending action, which is the same count as the other four examiners.
With 5 distinct examiners and 3 distinct art units, the prosecution of the 5 pending office actions is moderately spread out. The focus on 3 art units allows for some specialization in technical arguments, even though 5 different examiners are involved. Practitioners should analyze the tendencies of Robinson, Hope A and the other examiners within the context of these 3 specific art units.
The strategy for these 5 pending office actions should account for the specific standards of the 3 distinct art units. While Robinson, Hope A is the busiest examiner, their influence is limited to a single action. Therefore, the prosecution team must remain flexible and adapt to the unique requirements of each of the 5 examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| Double-patenting + other | 1 (20%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROBINSON, HOPE A | 1 | 67.7% | +43.0% |
| MISHRA, DEEPA | 1 | 28.9% | +35.5% |
| MAHADEVAN, JANAKI ANANTH | 1 | 0.0% | +0.0% |
| CREWS, JARET JAMES | 1 | 43.9% | +71.3% |
| PAK, YONG D | 1 | 74.7% | +14.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | — |
| 18729290 | GENETICALLY MODIFIED BACTERIA RESISTANT TO MASS CELL LYSIS | MISHRA, DEEPA | — |
| 18563056 | NOVEL SPINOSYN COMPOUNDS | MAHADEVAN, JANAKI ANANTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18037918 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | PAK, YONG D | 28d |
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | — |
| 18729290 | GENETICALLY MODIFIED BACTERIA RESISTANT TO MASS CELL LYSIS | MISHRA, DEEPA | — |
| 18556489 | NOVEL SPINOSYN PRODRUGS | CREWS, JARET JAMES | — |
| Art Unit | Apps |
|---|---|
| 1652 | 2 |
| 1693 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18881959 | PEROXIDASE BASED BIOCONTROL AGENTS | ROBINSON, HOPE A | 1652 | §102§112 | Non-Final OA | — | Pending | Jan 07, 2025 |
| 18729290 | GENETICALLY MODIFIED BACTERIA RESISTANT TO MASS CELL LYSIS | MISHRA, DEEPA | — | §102§103§112 | Non-Final OA | — | Pending | Jul 16, 2024 |
| 18563056 | NOVEL SPINOSYN COMPOUNDS | MAHADEVAN, JANAKI ANANTH | 1693 | §103DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18556489 | NOVEL SPINOSYN PRODRUGS | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | — | Pending | Oct 20, 2023 |
| 18037918 | GENETICALLY ENGINEERED BACTERIUM CAPABLE OF PRODUCING CYTOKININS WITH ISOPRENOID SIDE CHAINS | PAK, YONG D | 1652 | §103 | Final Rejection | 28d | Pending | May 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAcies Bio D O O has 5 pending office actions as of October 2026, spread across 3 art units and 5 examiners.
Hope A Robinson has the most, with 1 of Acies Bio D O O's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
